| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 16 | 2026 | 111 | 2.890 |
Why?
|
| Breast Neoplasms | 20 | 2026 | 2602 | 2.060 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2026 | 821 | 1.260 |
Why?
|
| Receptors, Estrogen | 7 | 2026 | 732 | 0.970 |
Why?
|
| Estrogen Receptor alpha | 6 | 2023 | 431 | 0.940 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2026 | 280 | 0.840 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 251 | 0.690 |
Why?
|
| Endocytosis | 3 | 2011 | 121 | 0.660 |
Why?
|
| Neurofibromin 1 | 4 | 2026 | 57 | 0.650 |
Why?
|
| Proteomics | 13 | 2026 | 615 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2025 | 50 | 0.600 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2025 | 66 | 0.600 |
Why?
|
| Neoplasms | 6 | 2024 | 3016 | 0.590 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1826 | 0.550 |
Why?
|
| Gene Fusion | 1 | 2018 | 58 | 0.550 |
Why?
|
| Receptors, Interleukin-5 | 2 | 2008 | 5 | 0.530 |
Why?
|
| Neoadjuvant Therapy | 4 | 2026 | 400 | 0.460 |
Why?
|
| Biomarkers, Tumor | 6 | 2026 | 1586 | 0.440 |
Why?
|
| Signal Transduction | 9 | 2025 | 4686 | 0.410 |
Why?
|
| Lysine | 2 | 2011 | 167 | 0.390 |
Why?
|
| Ubiquitination | 2 | 2021 | 173 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 4 | 2026 | 386 | 0.370 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2011 | 1 | 0.350 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.350 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 254 | 0.350 |
Why?
|
| Cell Line, Tumor | 11 | 2026 | 3748 | 0.330 |
Why?
|
| Eosinophils | 2 | 2008 | 122 | 0.320 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 138 | 0.320 |
Why?
|
| Mutation | 10 | 2026 | 6099 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 633 | 0.300 |
Why?
|
| Humans | 45 | 2026 | 131163 | 0.290 |
Why?
|
| Precision Medicine | 2 | 2023 | 388 | 0.280 |
Why?
|
| Transferrin | 1 | 2008 | 46 | 0.280 |
Why?
|
| src-Family Kinases | 2 | 2016 | 92 | 0.270 |
Why?
|
| Protein Kinases | 3 | 2025 | 312 | 0.260 |
Why?
|
| Metabolomics | 3 | 2026 | 501 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2026 | 2026 | 0.250 |
Why?
|
| Female | 29 | 2026 | 70963 | 0.250 |
Why?
|
| Janus Kinases | 1 | 2007 | 36 | 0.250 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2026 | 359 | 0.250 |
Why?
|
| Ubiquitin | 1 | 2007 | 128 | 0.240 |
Why?
|
| Osteoclasts | 1 | 2026 | 69 | 0.230 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 8 | 0.220 |
Why?
|
| Software | 3 | 2025 | 733 | 0.220 |
Why?
|
| Phosphorylation | 6 | 2025 | 1571 | 0.220 |
Why?
|
| Tumor Microenvironment | 5 | 2026 | 713 | 0.220 |
Why?
|
| Down-Regulation | 1 | 2007 | 645 | 0.220 |
Why?
|
| Phosphoproteins | 2 | 2025 | 448 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 86 | 0.210 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 15 | 0.210 |
Why?
|
| Gene Expression Profiling | 4 | 2026 | 1801 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2024 | 130 | 0.200 |
Why?
|
| Benzamides | 1 | 2024 | 127 | 0.200 |
Why?
|
| Nitriles | 1 | 2024 | 163 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 1011 | 0.200 |
Why?
|
| Computational Biology | 2 | 2025 | 862 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1545 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2025 | 2465 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 110 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 70 | 0.180 |
Why?
|
| Genomics | 5 | 2026 | 1621 | 0.180 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 357 | 0.180 |
Why?
|
| Proteome | 1 | 2023 | 285 | 0.170 |
Why?
|
| Metformin | 1 | 2023 | 174 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 475 | 0.170 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 408 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 478 | 0.160 |
Why?
|
| Machine Learning | 1 | 2024 | 387 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2026 | 572 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2026 | 614 | 0.150 |
Why?
|
| Prognosis | 3 | 2025 | 4886 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1336 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 236 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 127 | 0.150 |
Why?
|
| Claudins | 1 | 2018 | 29 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2024 | 1240 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2025 | 972 | 0.140 |
Why?
|
| Mitosis | 1 | 2018 | 191 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2020 | 336 | 0.130 |
Why?
|
| MutL Proteins | 1 | 2017 | 14 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 960 | 0.130 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 37 | 0.130 |
Why?
|
| Mice | 9 | 2026 | 18301 | 0.120 |
Why?
|
| Protein Binding | 3 | 2021 | 1652 | 0.120 |
Why?
|
| Transfection | 1 | 2018 | 962 | 0.120 |
Why?
|
| Animals | 12 | 2026 | 33912 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 394 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2018 | 401 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 750 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2016 | 79 | 0.110 |
Why?
|
| Protein Interaction Maps | 2 | 2026 | 93 | 0.110 |
Why?
|
| Cell Movement | 1 | 2018 | 876 | 0.110 |
Why?
|
| Mice, Nude | 3 | 2021 | 700 | 0.110 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 209 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1029 | 0.100 |
Why?
|
| Pyridines | 2 | 2025 | 255 | 0.100 |
Why?
|
| Piperazines | 2 | 2025 | 265 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1373 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21025 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2024 | 768 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 631 | 0.090 |
Why?
|
| Endosomes | 1 | 2011 | 70 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 366 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 28601 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 801 | 0.070 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2008 | 6 | 0.070 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 14 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 12 | 0.070 |
Why?
|
| Clathrin | 1 | 2008 | 21 | 0.070 |
Why?
|
| Cholera Toxin | 1 | 2008 | 40 | 0.070 |
Why?
|
| Interleukin-5 | 1 | 2008 | 49 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2023 | 594 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 155 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12936 | 0.070 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 57 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2021 | 286 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2007 | 13 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2550 | 0.060 |
Why?
|
| Apoptosis | 2 | 2024 | 1827 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2026 | 41 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 450 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2007 | 249 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 765 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 241 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2026 | 230 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6797 | 0.060 |
Why?
|
| Databases, Protein | 1 | 2025 | 63 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 743 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 722 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 82 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 106 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2025 | 59 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 42 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2025 | 140 | 0.050 |
Why?
|
| Benchmarking | 1 | 2025 | 137 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 223 | 0.050 |
Why?
|
| Phosphopeptides | 1 | 2023 | 26 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 573 | 0.050 |
Why?
|
| Adult | 5 | 2024 | 31282 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4697 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2023 | 39 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 219 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 46 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 176 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 88 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 118 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2023 | 115 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 99 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 79 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 298 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 373 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 197 | 0.040 |
Why?
|
| Cell Line | 1 | 2007 | 2552 | 0.040 |
Why?
|
| Cell Division | 1 | 2023 | 718 | 0.040 |
Why?
|
| Models, Biological | 1 | 2007 | 1371 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2021 | 18 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 393 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 155 | 0.040 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2021 | 35 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2885 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 190 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 708 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 480 | 0.040 |
Why?
|
| Microbiota | 1 | 2026 | 438 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 78 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5063 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 414 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 975 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 38 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 189 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 91 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 324 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 140 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 37 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 116 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1129 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 27 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 585 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 67 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 59 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2020 | 348 | 0.030 |
Why?
|
| Male | 5 | 2025 | 64957 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2023 | 993 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 191 | 0.030 |
Why?
|
| Algorithms | 1 | 2025 | 1680 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 378 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2020 | 556 | 0.030 |
Why?
|
| DNA Repair | 1 | 2020 | 571 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 511 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 680 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 81 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 358 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 419 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2114 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 24 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 19 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 344 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2200 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 992 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 77 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 108 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 146 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1590 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 325 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1103 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 335 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2018 | 760 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 289 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1363 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 653 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6459 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1211 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2008 | 33 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 45 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 67 | 0.020 |
Why?
|
| Turner Syndrome | 1 | 2008 | 44 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 308 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 335 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 10103 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 759 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 2595 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 15110 | 0.010 |
Why?
|